Homepage Top Section2

Keytruda is the first anti-PD-1 therapy approved in combination with chemotherapy in Europe for first-line use in patients with metastatic NSCLC. The European approval is for the first-line

Cablivi is claimed to be the first therapeutic specifically developed to treat aTTP, a rare blood-clotting disorder. The approval was based on data from the phase II Titan

Delstrigo is a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg). Pifeltro (doravirine, 100mg) is a new non-nucleoside reverse transcriptase

KaNDy is focused on optimizing the potential of NT-814 as a non-hormonal treatment for common, chronic debilitating female sex-hormone associated conditions. The funding came from new US investor

CogniCann is one of MXC’s medical cannabis pharmaceutical products with a THC:CBD ratio specifically formulated to treat key Dementia symptoms and enhance specific cognitive functions. The approval was

The agreement will not include South Korea where JWP will retain its exclusivity over the JW1601 drug, which was developed by one of its affiliates – C&C Research

NK is a rare and progressive eye disease, which may result in corneal scarring and vision loss. The FDA has approved Oxervate eye drops for use in adults

The partnership will assess Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy in a phase 2 study in patients with metastatic triple negative breast cancer (TNBC). The trial has been